Catégorie : Substances psychédéliques et therapeutique

Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder, Ingmar Gorman et al., 2020

Posttraumatic Growth After MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder Ingmar Gorman, Alexander B. Belser, Lisa Jerome, Colin Hennigan, Ben Shechet, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, and Allison A. Feduccia Journal of Traumatic Stress, 2020, 1-10. Doi : 10.1002/jts.22479   3,4-Methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but posttraumatic growth (PTG), which consists of positive changes in self-perception, interpersonal relationships, or philosophy of life, has not been studied with this treatment. Participant data (n = 60) were pooled from three Phase 2 clinical studies employing triple-blind crossover designs. Participants were required to meet DSM-IV-R criteria for [...]

Lire la suite

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline, Allison A. Feduccia et al., 2019

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer and Rick Doblin Frontiers in Psychiatry, 2019, Volume 10, Article 650. doi: 10.3389/fpsyt.2019.00650   Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and lifethreatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for Psychedelic Studies (MAPS) obtained Breakthrough Therapy Designation (BTD) from the FDA for 3,4 methylenedioxymethamphetamine [...]

Lire la suite

Serotonin 2A Receptor Signaling Underlies LSDinduced Alteration of the Neural Response to Dynamic Changes in Music, Frederick S. Barrett et al., 2018

Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music Frederick S. Barrett, Katrin H. Preller, Marcus Herdener, Petr Janata and Franz X. Vollenweider Cerebral Cortex, November 2018, 28, 3939–3950. doi : 10.1093/cercor/bhx257   Abstract Classic psychedelic drugs (serotonin 2A, or 5HT2A, receptor agonists) have notable effects on music listening. In the current report, blood oxygen level-dependent (BOLD) signal was collected during music listening in 25 healthy adults after administration of placebo, lysergic acid diethylamide (LSD), and LSD pretreated with the 5HT2A antagonist ketanserin, to investigate the role of 5HT2A receptor signaling in the neural response to the time-varying tonal [...]

Lire la suite

Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States : A Pharmacological fMRI Study, Katrin H. Preller et al., 2018

Role of the 5-HT2A Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States : A Pharmacological fMRI Study Katrin H. Preller, Leonhard Schilbach, Thomas Pokorny, Jan Flemming, Erich Seifritz, and Franz X. Vollenweider The Journal of Neuroscience, 2018, 38, (14), 3603–3611. Doi : 10.1523/JNEUROSCI.1939-17.2018   Distortions of self-experience are critical symptoms of psychiatric disorders and have detrimental effects on social interactions. In light of the immense need for improved and targeted interventions for social impairments, it is important to better understand the neurochemical substrates of social interaction abilities. We therefore investigated the pharmacological and neural correlates of self- and other-initiated social interaction. In [...]

Lire la suite

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts, Natasha L. Mason et al., 2020,

Reported effects of psychedelic use on those with low well-being given various emotional states and social contexts Natasha L. Mason, Patrick C. Dolder and Kim P.C. Kuypers Drug Science, Policy and Law, 2020, Volume 6, 1–11. Doi : 10.1177/2050324519900068   Abstract Background : It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use psychedelics, and the outcome [...]

Lire la suite

Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized- Controlled Clinical Trials, Juan Jose Fuentes et al., 2020

Therapeutic Use of LSD in Psychiatry : A Systematic Review of Randomized-Controlled Clinical Trials Juan José Fuentes, Francina Fonseca, Matilde Elices, Magí Farré and Marta Torrens Frontiers in Psychiatry, 2020, Vol 10, Article 943. doi : 10.3389/fpsyt.2019.00943   Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a resurgence of interest in LSD research and [...]

Lire la suite

Therapeutic Potential of Psychedelic Drugs, Justin Briglio, 2015

Therapeutic Potential of Psychedelic Drugs Justin Briglio University of Maine, 2015, 31 p.   Table of Contents Introduction......................................................................................................................................3 History of Psychedelic Research.....................................................................................................6 Recent Research...............................................................................................................................8 Neurobiology of Psychedelics.........................................................................................................9 Therapeutic Potential of Psilocybin...............................................................................................12 Therapeutic Potential of LSD........................................................................................................15 Therapeutic Potential of Ayahuasca..............................................................................................19 Therapeutic Potential of Ibogaine..................................................................................................22 Conclusion.....................................................................................................................................26 References......................................................................................................................................28 A psychedelic compound is a psychoactive drug whose main action is to alter perception and cognition. Psychedelics are distinctive from other psychoactive drugs in that they alter the mind, whereas opiates or stimulants alter the mood (Meyer & Quenzer, 2013). Psychedelics affect nature of consciousness itself and access otherwise unknown states of consciousness, as opposed to affecting the degree or extent of one's consciousness and inducing proverbial moods such as [...]

Lire la suite

LSD : microdoses festives, Céline Zünd, Le Temps, mardi 28 janvier 2020

LSD : microdoses festives Céline ZÜND Le Temps, mardi 28 janvier 2020 https://www.letemps.ch/societe/lsd-microdoses-festives?utm_campaign=article_traffic&utm_content=1580242382&utm_medium=social&utm_source=facebook&fbclid=IwAR3v1uDm_lCzk_Bb1XMeRzSxcxr-mHObGhhPeJVK-Fa0y6rczvc3DFJ3H78   La prise de LSD en petites quantités fait toujours plus d'adeptes, dans les milieux festifs, au travail ou en automédication. Or la recherche scientifique ne dispose pas de données fiables sur les véritables effets de cette substance, ni sur ses risques potentiels. Ursina s’est longtemps refusée à la tentation d’accompagner ses nuits festives de substances chimiques. «J’avais peur du mauvais trip», dit la Zurichoise de 40 ans, casquette et bomber satiné. Jusqu’à ce qu’elle entende parler du LSD en microdose. Elle se procure l’hallucinogène une première fois il y [...]

Lire la suite

Entheogens, Katie Givens Kime, 2018

Entheogens Katie Givens Kime Institute of Practical Theology, University of Bern, Bern, Switzerland in D. A. Leeming (ed.), "Encyclopedia of Psychology and Religion", # Springer-Verlag GmbH Germany, part of Springer Nature 2018 Doi : 10.1007/978-3-642-27771-9_200181-1   Entheogen is a term coined in the late 1970s by a group of botanists and scholars which refers to any psychoactive agent which allows for “generating the divine within” (Ruck et al. 1979). Entheogens are psychedelic substances which, in adequate dosage under supportive conditions, are known to facilitate visionary, mystical, and/or spiritual experiences. Such substances include psilocybin, peyote, LSD (lysergic acid diethylamide), ibogaine, and ayahuasca. Typically of plant origin, entheogens are [...]

Lire la suite